Company Filing History:

5 out of 3,580

American Cyanamid Company

patents

3 out of 1,567

American Home Products Corporation

Wyeth Holdings Corporation

patents

5. 1 out of 832,843

Other

patents

Years Active: 1996-2010

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7671056 - [object Object] (2010-03-02),

2. 7276603 - Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use (2007-10-02),

3. 6825354 - Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and TACE inhibitors (2004-11-30),

4. 6462073 - N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors (2002-10-08),

5. 6342508 - N-hydroxy-2-(Alkyl,Aryl or Heteroaryl sulfanyl, sulfinyl or sulfonyl) 3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors (2002-01-29),

6. 6340691 - Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors (2002-01-22),

7. 6331563 - N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase inhibitors (2001-12-18),

8. 6197791 - N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors (2001-03-06),

9. 6172057 - N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors (2001-01-09),

10. 5914339 - Substituted 1,3-benzodioxoles (1999-06-22),

11. 5780471 - Tricyclic benzazepine vasopressin antagonists (1998-07-14),

12. 5521173 - Tricyclic benzazepine vasopressin antagonists (1996-05-28),

Title: The Innovative Journey of George Theodore Grosu

Introduction: George Theodore Grosu is a distinguished inventor based in Pearl River, NY, whose innovative contributions to the field of pharmaceuticals have resulted in a total of 12 patents. His work predominantly focuses on compounds that serve as important agents in treating various central nervous system disorders.

Latest Patents: Grosu's latest patents include the development of novel piperazine-piperidine compounds, designed to function as 5-HT1A binding agents. These compounds are particularly significant as they assist in treating cognition disorders, anxiety, depression, and sexual dysfunction. The invention details the pharmaceutical compositions containing these compounds, specifically salts of the defined formula. Additionally, he has contributed to the formulation of benzofuranyl- and benzothienyl-piperazinyl quinolines. These compounds are disclosed as potential treatments for serotonin-related disorders such as anxiety and depression, reflecting Grosu's commitment to addressing pressing mental health issues.

Career Highlights: Throughout his career, Grosu has made impactful contributions while working for prominent companies, including the American Cyanamid Company and American Home Products Corporation. His tenure at these organizations has allowed him to harness his expertise in pharmaceutical development and innovation.

Collaborations: Grosu has collaborated with various professionals in his field, including his coworkers Aranapakam Mudumbai Venkatesan and Jamie Marie Davis. These collaborations have further enriched his research and patent developments, bolstering the effectiveness of his inventions.

Conclusion: George Theodore Grosu's journey as an inventor is characterized by his relentless pursuit of innovative solutions for treating mental health disorders. With an impressive portfolio of patents that reflect his expertise, Grosu continues to make a significant impact in the pharmaceutical industry, demonstrating the vital role of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com